GlassScriptPhysician profile
Nicole Miller
NPI 1114343746
$13,699.83
in general payments reported to CMS, 2019-2025
36 companies · $1,233 in 2025
The $1,233 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,479 · 2022: $4,005 · 2023: $3,140 · 2024: $1,843 · 2025: $1,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,215.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,089.27 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,083.05 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,048.63 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $946.58 | 2021-2024 | Caplyta |
| Axsome Therapeutics, INC. | $927.70 | 2022-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $746.39 | 2021-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $682.88 | 2021-2024 | Austedo Xr, Austedo, Uzedy |
| Vanda Pharmaceuticals INC. | $679.82 | 2021-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $675.00 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $536.58 | 2021-2022 | |
| Alkermes, INC. | $516.45 | 2021-2023 | Aristada, Lybalvi |
| Jazz Pharmaceuticals INC. | $377.14 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $338.85 | 2021-2024 | Spravato |
| Bausch Health US, LLC | $233.97 | 2021-2023 | Aplenzin |
| Corium, LLC | $233.72 | 2022-2023 | Azstarys |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $214.62 | 2022-2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $155.62 | 2021-2023 | Trintellix |
| Indivior INC. | $147.27 | 2021-2024 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $123.75 | 2024 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $121.21 | 2022-2023 | Jornay Pm |
| Merck Sharp & Dohme LLC | $119.28 | 2022-2023 | Belsomra |
| Acadia Pharmaceuticals INC | $116.39 | 2021-2022 | |
| Tris Pharma INC | $110.00 | 2022 | |
| Arbor Pharmaceuticals, INC. | $94.59 | 2021-2022 | |
| Livanova USA, INC. | $78.83 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Almatica Pharma LLC | $55.64 | 2022 | |
| Alfasigma USA, INC. | $39.26 | 2021-2022 | |
| Eisai INC. | $36.19 | 2022 | |
| Neos Therapeutics, LP | $33.24 | 2022-2023 | Adzenys Xr-Odt |
| Orexo US, INC. | $29.21 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $29.09 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $28.28 | 2021 | |
| Collegium Pharmaceutical, INC. | $22.44 | 2023 | Belbuca |
| Brainsway USA INC | $12.78 | 2022 | |
| Horizon Therapeutics Plc | $12.71 | 2021 | |
| Ge Healthcare | $3.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.